$295 Million is the total value of Krensavage Asset Management, LLC's 13 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| REGN | Sell | REGENERON PHARMACEUTICALS | $45,858,000 | +17.2% | 82,104 | -0.7% | 15.57% | +15.0% |
| ALKS | Buy | ALKERMES PLC | $41,410,000 | +36.2% | 1,688,841 | +3.8% | 14.06% | +33.6% |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $41,354,000 | -2.8% | 939,650 | +8.9% | 14.04% | -4.7% |
| UTHR | Sell | UNITED THERAPEUTICS CORP | $39,415,000 | -5.5% | 219,690 | -11.9% | 13.38% | -7.3% |
| TARO | Sell | TARO PHARMACEUTICAL INDUS | $39,125,000 | -3.1% | 543,705 | -0.7% | 13.28% | -5.0% |
| BIIB | Sell | BIOGEN INC | $33,769,000 | -12.9% | 97,523 | -29.6% | 11.46% | -14.5% |
| MCK | Sell | MCKESSON CORP | $31,829,000 | -2.7% | 166,436 | -0.7% | 10.81% | -4.5% |
| SRGA | Sell | SURGALIGN HOLDINGS INC | $8,900,000 | -36.7% | 6,403,077 | -0.7% | 3.02% | -37.9% |
| IVC | Sell | INVACARE CORP | $7,277,000 | -0.1% | 901,712 | -0.7% | 2.47% | -2.0% |
| EGRX | New | EAGLE PHARMACEUTICALS INC | $3,030,000 | – | 70,804 | +100.0% | 1.03% | – |
| TVTX | New | TRAVERE THERAPEUTICS INC | $2,043,000 | – | 140,000 | +100.0% | 0.69% | – |
| ANAB | Sell | ANAPTYSBIO INC | $282,000 | -49.1% | 10,890 | -57.6% | 0.10% | -50.0% |
| NXTC | Buy | NEXTCURE INC | $252,000 | -17.6% | 31,355 | +2.5% | 0.09% | -18.9% |
| ALXN | Exit | ALEXION PHARMACEUTICALS INC | $0 | – | -6,912 | -100.0% | -0.37% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP | 36 | Q3 2023 | 18.1% |
| Enanta Pharmceuticals Inc | 35 | Q3 2023 | 16.7% |
| INVACARE CORP | 28 | Q3 2021 | 5.8% |
| RTI SURGICAL INC | 23 | Q2 2020 | 7.9% |
| MCKESSON CORP | 20 | Q3 2022 | 16.3% |
| BIOGEN INC | 19 | Q3 2023 | 16.0% |
| MERCK & CO. INC. | 18 | Q1 2019 | 11.1% |
| DIGIRAD CORP | 18 | Q1 2019 | 1.0% |
| REGENERON PHARMACEUTICALS | 16 | Q3 2023 | 16.1% |
| ALKERMES PLC | 16 | Q3 2023 | 14.1% |
View Krensavage Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SURGALIGN HOLDINGS, INC. | February 19, 2021 | 5,380,449 | 6.6% |
| RTI SURGICAL, INC. | February 14, 2019 | 3,852,567 | 6.1% |
| Aviragen Therapeutics, Inc. | February 15, 2018 | 2,292,058 | 5.9% |
| ENANTA PHARMACEUTICALS INC | February 15, 2017 | 883,902 | 4.6% |
| Biota Pharmaceuticals, Inc. | February 17, 2016 | 2,267,655 | 5.9% |
View Krensavage Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SCHEDULE 13G | 2024-02-27 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-15 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-16 |
| 13F-HR | 2023-02-15 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-17 |
| 13F-HR | 2022-02-15 |
View Krensavage Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.